Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
9
NIVF Quote, Financials, Valuation and Earnings
Last price:
$0.89
Seasonality move
:
-23.38%
Day range:
$0.80 - $0.90
52-week range:
$0.78 - $2,450.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.96x
Volume:
326K
Avg. volume:
995K
1-year change:
-99.95%
Market cap:
$1.2M
Revenue:
$5.4M
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NIVF
NewGenIVF Group Ltd.
|
-- | -- | -- | -- | -- |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
BDULF
Bangkok Dusit Medical Services Public Co. Ltd.
|
-- | -- | -- | -- | -- |
|
BUHPF
Bumrungrad Hospital Public Co., Ltd.
|
-- | -- | -- | -- | -- |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$198K | -$0.02 | -24.9% | -15.25% | $3.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NIVF
NewGenIVF Group Ltd.
|
$0.90 | -- | $1.2M | -- | $0.00 | 0% | -- |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
BDULF
Bangkok Dusit Medical Services Public Co. Ltd.
|
$0.61 | -- | $9.6B | 74.69x | $0.01 | 3.74% | 3.11x |
|
BUHPF
Bumrungrad Hospital Public Co., Ltd.
|
$5.35 | -- | $4.3B | 90.83x | $0.06 | 2.8% | 5.70x |
|
CVM
CEL-SCI Corp.
|
$4.91 | $42.50 | $14.9M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.88 | $27.9M | -- | $0.00 | 0% | 22.51x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NIVF
NewGenIVF Group Ltd.
|
-- | 0.341 | -- | -- |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
BDULF
Bangkok Dusit Medical Services Public Co. Ltd.
|
7.11% | -0.653 | 2.09% | 1.12x |
|
BUHPF
Bumrungrad Hospital Public Co., Ltd.
|
0.08% | 0.217 | 0.02% | 4.40x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NIVF
NewGenIVF Group Ltd.
|
-- | -- | -- | -- | -- | -- |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
BDULF
Bangkok Dusit Medical Services Public Co. Ltd.
|
-- | $165.3M | 14.38% | 15.71% | 20.2% | $129.4M |
|
BUHPF
Bumrungrad Hospital Public Co., Ltd.
|
-- | $68.7M | 26.98% | 27.01% | 38.69% | $36.6M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
NewGenIVF Group Ltd. vs. Competitors
-
Which has Higher Returns NIVF or AIM?
AIM ImmunoTech has a net margin of -- compared to NewGenIVF Group Ltd.'s net margin of -10571.43%. NewGenIVF Group Ltd.'s return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital NIVFNewGenIVF Group Ltd.-- -- -- AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About NIVF or AIM?
NewGenIVF Group Ltd. has a consensus price target of --, signalling upside risk potential of 8253.75%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than NewGenIVF Group Ltd., analysts believe AIM ImmunoTech is more attractive than NewGenIVF Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NIVFNewGenIVF Group Ltd.0 0 0 AIMAIM ImmunoTech1 0 0 -
Is NIVF or AIM More Risky?
NewGenIVF Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock NIVF or AIM?
NewGenIVF Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewGenIVF Group Ltd. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NIVF or AIM?
NewGenIVF Group Ltd. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. NewGenIVF Group Ltd.'s net income of -- is lower than AIM ImmunoTech's net income of -$3.7M. Notably, NewGenIVF Group Ltd.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewGenIVF Group Ltd. is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NIVFNewGenIVF Group Ltd.-- -- -- -- AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns NIVF or BDULF?
Bangkok Dusit Medical Services Public Co. Ltd. has a net margin of -- compared to NewGenIVF Group Ltd.'s net margin of 15.48%. NewGenIVF Group Ltd.'s return on equity of -- beat Bangkok Dusit Medical Services Public Co. Ltd.'s return on equity of 15.71%.
Company Gross Margin Earnings Per Share Invested Capital NIVFNewGenIVF Group Ltd.-- -- -- BDULFBangkok Dusit Medical Services Public Co. Ltd.37.03% -- $3.4B -
What do Analysts Say About NIVF or BDULF?
NewGenIVF Group Ltd. has a consensus price target of --, signalling upside risk potential of 8253.75%. On the other hand Bangkok Dusit Medical Services Public Co. Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that NewGenIVF Group Ltd. has higher upside potential than Bangkok Dusit Medical Services Public Co. Ltd., analysts believe NewGenIVF Group Ltd. is more attractive than Bangkok Dusit Medical Services Public Co. Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NIVFNewGenIVF Group Ltd.0 0 0 BDULFBangkok Dusit Medical Services Public Co. Ltd.0 0 0 -
Is NIVF or BDULF More Risky?
NewGenIVF Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bangkok Dusit Medical Services Public Co. Ltd. has a beta of -0.025, suggesting its less volatile than the S&P 500 by 102.513%.
-
Which is a Better Dividend Stock NIVF or BDULF?
NewGenIVF Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bangkok Dusit Medical Services Public Co. Ltd. offers a yield of 3.74% to investors and pays a quarterly dividend of $0.01 per share. NewGenIVF Group Ltd. pays -- of its earnings as a dividend. Bangkok Dusit Medical Services Public Co. Ltd. pays out 74.55% of its earnings as a dividend. Bangkok Dusit Medical Services Public Co. Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NIVF or BDULF?
NewGenIVF Group Ltd. quarterly revenues are --, which are smaller than Bangkok Dusit Medical Services Public Co. Ltd. quarterly revenues of $826.7M. NewGenIVF Group Ltd.'s net income of -- is lower than Bangkok Dusit Medical Services Public Co. Ltd.'s net income of $127.9M. Notably, NewGenIVF Group Ltd.'s price-to-earnings ratio is -- while Bangkok Dusit Medical Services Public Co. Ltd.'s PE ratio is 74.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewGenIVF Group Ltd. is -- versus 3.11x for Bangkok Dusit Medical Services Public Co. Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NIVFNewGenIVF Group Ltd.-- -- -- -- BDULFBangkok Dusit Medical Services Public Co. Ltd.3.11x 74.69x $826.7M $127.9M
-
Which has Higher Returns NIVF or BUHPF?
Bumrungrad Hospital Public Co., Ltd. has a net margin of -- compared to NewGenIVF Group Ltd.'s net margin of 30.84%. NewGenIVF Group Ltd.'s return on equity of -- beat Bumrungrad Hospital Public Co., Ltd.'s return on equity of 27.01%.
Company Gross Margin Earnings Per Share Invested Capital NIVFNewGenIVF Group Ltd.-- -- -- BUHPFBumrungrad Hospital Public Co., Ltd.52.46% -- $887.3M -
What do Analysts Say About NIVF or BUHPF?
NewGenIVF Group Ltd. has a consensus price target of --, signalling upside risk potential of 8253.75%. On the other hand Bumrungrad Hospital Public Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that NewGenIVF Group Ltd. has higher upside potential than Bumrungrad Hospital Public Co., Ltd., analysts believe NewGenIVF Group Ltd. is more attractive than Bumrungrad Hospital Public Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NIVFNewGenIVF Group Ltd.0 0 0 BUHPFBumrungrad Hospital Public Co., Ltd.0 0 0 -
Is NIVF or BUHPF More Risky?
NewGenIVF Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bumrungrad Hospital Public Co., Ltd. has a beta of -0.048, suggesting its less volatile than the S&P 500 by 104.845%.
-
Which is a Better Dividend Stock NIVF or BUHPF?
NewGenIVF Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bumrungrad Hospital Public Co., Ltd. offers a yield of 2.8% to investors and pays a quarterly dividend of $0.06 per share. NewGenIVF Group Ltd. pays -- of its earnings as a dividend. Bumrungrad Hospital Public Co., Ltd. pays out 51.12% of its earnings as a dividend. Bumrungrad Hospital Public Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NIVF or BUHPF?
NewGenIVF Group Ltd. quarterly revenues are --, which are smaller than Bumrungrad Hospital Public Co., Ltd. quarterly revenues of $181.9M. NewGenIVF Group Ltd.'s net income of -- is lower than Bumrungrad Hospital Public Co., Ltd.'s net income of $56.1M. Notably, NewGenIVF Group Ltd.'s price-to-earnings ratio is -- while Bumrungrad Hospital Public Co., Ltd.'s PE ratio is 90.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewGenIVF Group Ltd. is -- versus 5.70x for Bumrungrad Hospital Public Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NIVFNewGenIVF Group Ltd.-- -- -- -- BUHPFBumrungrad Hospital Public Co., Ltd.5.70x 90.83x $181.9M $56.1M
-
Which has Higher Returns NIVF or CVM?
CEL-SCI Corp. has a net margin of -- compared to NewGenIVF Group Ltd.'s net margin of --. NewGenIVF Group Ltd.'s return on equity of -- beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital NIVFNewGenIVF Group Ltd.-- -- -- CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About NIVF or CVM?
NewGenIVF Group Ltd. has a consensus price target of --, signalling upside risk potential of 8253.75%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 765.58%. Given that NewGenIVF Group Ltd. has higher upside potential than CEL-SCI Corp., analysts believe NewGenIVF Group Ltd. is more attractive than CEL-SCI Corp..
Company Buy Ratings Hold Ratings Sell Ratings NIVFNewGenIVF Group Ltd.0 0 0 CVMCEL-SCI Corp.1 0 0 -
Is NIVF or CVM More Risky?
NewGenIVF Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock NIVF or CVM?
NewGenIVF Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewGenIVF Group Ltd. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NIVF or CVM?
NewGenIVF Group Ltd. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. NewGenIVF Group Ltd.'s net income of -- is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, NewGenIVF Group Ltd.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewGenIVF Group Ltd. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NIVFNewGenIVF Group Ltd.-- -- -- -- CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns NIVF or IGC?
IGC Pharma, Inc. has a net margin of -- compared to NewGenIVF Group Ltd.'s net margin of -953.4%. NewGenIVF Group Ltd.'s return on equity of -- beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital NIVFNewGenIVF Group Ltd.-- -- -- IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About NIVF or IGC?
NewGenIVF Group Ltd. has a consensus price target of --, signalling upside risk potential of 8253.75%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1191.67%. Given that NewGenIVF Group Ltd. has higher upside potential than IGC Pharma, Inc., analysts believe NewGenIVF Group Ltd. is more attractive than IGC Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NIVFNewGenIVF Group Ltd.0 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is NIVF or IGC More Risky?
NewGenIVF Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock NIVF or IGC?
NewGenIVF Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NewGenIVF Group Ltd. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NIVF or IGC?
NewGenIVF Group Ltd. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. NewGenIVF Group Ltd.'s net income of -- is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, NewGenIVF Group Ltd.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NewGenIVF Group Ltd. is -- versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NIVFNewGenIVF Group Ltd.-- -- -- -- IGCIGC Pharma, Inc.22.51x -- $191K -$1.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
